Karyopharm Therapeutics filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech, Ayrmid. Massachusetts-based Karyopharm’s financial woes came to a head in August, when ...
Dexcom has also tapped Chris Megino, who has built an online following sharing his journey with type 2 diabetes, and Chelsea ...
The direct-to-patient (DTP) market is full of providers making bold claims. But claims are not outcomes. | The DTP space is ...
After an initial FDA scare that threatened its path for an accelerated approval, Inovio’s Voceryq, the first plasmid DNA-based immunotherapy, has earned a go-ahead to treat a rare HPV-driven disease.
The survey results flesh out the unmet need that Compass hopes to address. COMP360 is on track to become the first classic psychedelic treatment to win FDA approval. The first-mover advantage is ...
Sanofi has predicted that Dupixent will receive “the majority of the benefit” from the direct-to-consumer (DTC) marketing ca ...
In total, Fresenius aims to expand its biosimilar portfolio to as many as 66 molecules, targeting branded drugs with combined sales of more than 370 billion euros at list prices. The company’s nine ...
Even as AbbVie has demonstrated that Rinvoq and Skyrizi sales can more than make up for Humira's tumble over the patent cliff ...
Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...
A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...
Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...
Vanda Pharmaceutical’s Nereus may soon break out of its motion sickness niche to become a treatment option for the burgeoning ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results